222 related articles for article (PubMed ID: 20939173)
1. [Recent advances in the study of accelerated blood clearance phenomenon of PEGylated liposomes].
Xu H; Wang KQ; Huang WW; Deng YH; Chen DW
Yao Xue Xue Bao; 2010 Jun; 45(6):677-83. PubMed ID: 20939173
[TBL] [Abstract][Full Text] [Related]
2. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
Ishida T; Atobe K; Wang X; Kiwada H
J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355
[TBL] [Abstract][Full Text] [Related]
3. Accelerated blood clearance of pegylated liposomal topotecan: influence of polyethylene glycol grafting density and animal species.
Li C; Cao J; Wang Y; Zhao X; Deng C; Wei N; Yang J; Cui J
J Pharm Sci; 2012 Oct; 101(10):3864-76. PubMed ID: 22777607
[TBL] [Abstract][Full Text] [Related]
4. Repeated injections of PEGylated liposomal topotecan induces accelerated blood clearance phenomenon in rats.
Ma Y; Yang Q; Wang L; Zhou X; Zhao Y; Deng Y
Eur J Pharm Sci; 2012 Apr; 45(5):539-45. PubMed ID: 22155543
[TBL] [Abstract][Full Text] [Related]
5. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes.
Ishida T; Ichihara M; Wang X; Kiwada H
J Control Release; 2006 Oct; 115(3):243-50. PubMed ID: 17011060
[TBL] [Abstract][Full Text] [Related]
6. Influence of phospholipid types and animal models on the accelerated blood clearance phenomenon of PEGylated liposomes upon repeated injection.
Xu H; Ye F; Hu M; Yin P; Zhang W; Li Y; Yu X; Deng Y
Drug Deliv; 2015; 22(5):598-607. PubMed ID: 24524364
[TBL] [Abstract][Full Text] [Related]
7. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration.
Abu Lila AS; Nawata K; Shimizu T; Ishida T; Kiwada H
Int J Pharm; 2013 Nov; 456(1):235-42. PubMed ID: 23928149
[TBL] [Abstract][Full Text] [Related]
8. Relationship between the concentration of anti-polyethylene glycol (PEG) immunoglobulin M (IgM) and the intensity of the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes in mice.
Hashimoto Y; Shimizu T; Abu Lila AS; Ishida T; Kiwada H
Biol Pharm Bull; 2015; 38(3):417-24. PubMed ID: 25757923
[TBL] [Abstract][Full Text] [Related]
9. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes.
Ishida T; Kiwada H
Int J Pharm; 2008 Apr; 354(1-2):56-62. PubMed ID: 18083313
[TBL] [Abstract][Full Text] [Related]
10. Influence of dose and animal species on accelerated blood clearance of PEGylated liposomal doxorubicin.
Suzuki T; Ichihara M; Hyodo K; Yamamoto E; Ishida T; Kiwada H; Kikuchi H; Ishihara H
Int J Pharm; 2014 Dec; 476(1-2):205-12. PubMed ID: 25280884
[TBL] [Abstract][Full Text] [Related]
11. T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes.
Koide H; Asai T; Hatanaka K; Akai S; Ishii T; Kenjo E; Ishida T; Kiwada H; Tsukada H; Oku N
Int J Pharm; 2010 Jun; 392(1-2):218-23. PubMed ID: 20227473
[TBL] [Abstract][Full Text] [Related]
12. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage.
Abu Lila AS; Kiwada H; Ishida T
J Control Release; 2013 Nov; 172(1):38-47. PubMed ID: 23933235
[TBL] [Abstract][Full Text] [Related]
13. Influence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in rats.
Wang XY; Ishida T; Ichihara M; Kiwada H
J Control Release; 2005 May; 104(1):91-102. PubMed ID: 15866337
[TBL] [Abstract][Full Text] [Related]
14. Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs.
Suzuki T; Ichihara M; Hyodo K; Yamamoto E; Ishida T; Kiwada H; Ishihara H; Kikuchi H
Int J Pharm; 2012 Oct; 436(1-2):636-43. PubMed ID: 22850293
[TBL] [Abstract][Full Text] [Related]
15. Particle size-dependent triggering of accelerated blood clearance phenomenon.
Koide H; Asai T; Hatanaka K; Urakami T; Ishii T; Kenjo E; Nishihara M; Yokoyama M; Ishida T; Kiwada H; Oku N
Int J Pharm; 2008 Oct; 362(1-2):197-200. PubMed ID: 18586076
[TBL] [Abstract][Full Text] [Related]
16. [Accelerated blood clearance (ABC) phenomenon induced by administration of PEGylated liposome].
Ishida T; Kiwada H
Yakugaku Zasshi; 2008 Feb; 128(2):233-43. PubMed ID: 18239370
[TBL] [Abstract][Full Text] [Related]
17. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes.
Wang X; Ishida T; Kiwada H
J Control Release; 2007 Jun; 119(2):236-44. PubMed ID: 17399838
[TBL] [Abstract][Full Text] [Related]
18. Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon.
Shimizu T; Ishida T; Kiwada H
Immunobiology; 2013 May; 218(5):725-32. PubMed ID: 22995937
[TBL] [Abstract][Full Text] [Related]
19. [Elucidation of accelerated blood clearance phenomenon caused by repeat injection of PEGylated nanocarriers].
Koide H; Asai T; Hatanaka K; Shimizu K; Yokoyama M; Ishida T; Kiwada H; Oku N
Yakugaku Zasshi; 2009 Dec; 129(12):1445-51. PubMed ID: 19952519
[TBL] [Abstract][Full Text] [Related]
20. Prolongation of time interval between doses could eliminate accelerated blood clearance phenomenon induced by pegylated liposomal topotecan.
Li C; Zhao X; Wang Y; Yang H; Li H; Li H; Tian W; Yang J; Cui J
Int J Pharm; 2013 Feb; 443(1-2):17-25. PubMed ID: 23318366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]